Table 3.
The dispensing interval for the ranibizumab and aflibercept cohorts at month 6 and month 12
| Ranibizumab cohort | Aflibercept cohort | |
|---|---|---|
| Month 6 (180 days) | ||
| No. of patients | 1235 | 959 |
| No. of dispensing intervals | 5292 | 3916 |
| Mean interval (days)a | 35.3 (19.2) | 36.8 (20.0) |
| Range (days) | 1.0–120.0 | 1.0–120.0 |
| Median (days)b | 31.0 (25.0–43.0) | 33.0 (25.0–47.0) |
| Adjusted mean difference (days)c | −1.59 (−2.51 to −0.67) | |
| Month 12 (360 days) | ||
| No. of patients | 578 | 483 |
| No. of dispensing intervals | 4591 | 3818 |
| Mean interval (days)a | 41.2 (20.9) | 41.6 (20.4) |
| Range (days) | 1.0–120.0 | 1.0–120.0 |
| Median (days)b | 37.0 (28.0–54.0) | 39.0 (28.0–55.0) |
| Adjusted mean difference (days)c | −0.40 (−1.70 to 0.91) | |
Mean differences were adjusted for baseline Medication-Based Disease Burden Index scores. Analyses were conducted with the final month 6 and month 12 study cohorts.
aThe standard deviation is given in parentheses
bThe interquartile range is given in parentheses
cThe 95% confidence interval is given in parentheses